Global cancer trial sets new standard for post-surgery chemotherapy
[CALGB 80702 - International Duration Evaluation in Adjuvant Chemotherapy (IDEA) Collaboration]
Read more.

Dr. Venook Discusses Adjuvant Chemotherapy Duration in CRC
[CALGB 80702 - International Duration Evaluation in Adjuvant Chemotherapy (IDEA) Collaboration]
View video.

Publication: Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
[CALGB 80702 - International Duration Evaluation in Adjuvant Chemotherapy (IDEA) Collaboration]
Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt, JA, Vernerey D, et al
N Engl J Med 2018; 378:1177-1188

Editorial: A New IDEA in Adjuvant Chemotherapy for Colon Cancer
[CALGB 80702 - International Duration Evaluation in Adjuvant Chemotherapy (IDEA) Collaboration]
An Editorial by Richard LK. Schilsky, MD
N Engl J Med 2018; 378:1242-1244

* * * * * *

Susan G. Komen® Welcomes Leaders in Health Equity, Novel Therapeutics, Bioinformatics and Advocacy to Renowned Breast Cancer Research Program
Mentions Lisa Carey, MD, Co-Chair of the Alliance Breast Committee as new member of Komen’s Scientific Advisory Board (SAB). Read more.

* * * * * *

Sorafenib improves progression-free survival for patients with rare sarcomas
[Alliance A091105]
Interim results from a randomised clinical trial for patients with desmoid tumours or aggressive fibromatosis (DT/DF) show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo. Based on these interim results, the data and safety monitoring board overseeing the trial recommended that the primary results of the study be released. “Sorafenib is a novel way of treating this rare cancer,” said lead investigator and study chair Dr. Mrinal M. Gounder, sarcoma medical oncologist at Memorial Sloan Kettering Cancer Center in New York City. “The promising results of this phase 3 trial represent a paradigm shift in the approach to the treatment of patients with desmoid tumors.” Read more.

NIH-funded study shows sorafenib improves progression-free survival for patients with rare sarcomas
[Alliance A091105]

Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis (DT/DF) show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo. Progression-free survival is the length of time patients lived before their disease worsened. Based on these interim results, the data and safety monitoring board overseeing the trial recommended that the primary results of the study be released. The trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH); designed and conducted by researchers with the Alliance for Clinical Trials in Oncology (Alliance); and supported by Bayer HealthCare AG, which provided the study drug. Read more.

Clinical Roundup Sorafenib improves PFS in rare sarcomas, NIH-funded study shows
[Alliance A091105]
The Cancer Letter article. Read more.

* * * * * *

Homing in on the Real Needs of Cancer Patients
[Former Co-Chair, Alliance Cancer in the Elderly Committee (now Alliance Cancer in the Older Adult Committee)]
"When you watch a tv show in the United States about cancer, the patients are always young or middle-aged. In reality, the average age of a person with a cancer diagnosis in this country is around 66 or 67, and the majority of people who die of cancer in the United States do so after age 65, so cancer is a disease of aging,” Hyman B Muss, MD, a 2017 Giants of Cancer Care® award winner and a pioneer in the treatment of older patients with cancer, said in an interview with OncLive. Read more. 

 

 

For other articles in this issue of the Alliance E-News newsletter, see below.